108 related articles for article (PubMed ID: 8078298)
1. Expression of an estrogen-induced breast cancer-associated protein (pS2) in benign and malignant human ovarian cysts.
Dante R; Ribieras S; Baldassini S; Martin V; Benzerara O; Bouteille C; Brémond A; Frappart L; Rio MC; Lasne Y
Lab Invest; 1994 Aug; 71(2):188-92. PubMed ID: 8078298
[TBL] [Abstract][Full Text] [Related]
2. Exon 5 deletion variant estrogen receptor messenger RNA expression in relation to tamoxifen resistance and progesterone receptor/pS2 status in human breast cancer.
Daffada AA; Johnston SR; Smith IE; Detre S; King N; Dowsett M
Cancer Res; 1995 Jan; 55(2):288-93. PubMed ID: 7812959
[TBL] [Abstract][Full Text] [Related]
3. Detection of pS2 messenger RNA in gynecological cancers.
Wysocki SJ; Hahnel E; Masters A; Smith V; McCartney AJ; Hahnel R
Cancer Res; 1990 Mar; 50(6):1800-2. PubMed ID: 2306733
[TBL] [Abstract][Full Text] [Related]
4. [Expression of pS2 protein in breast cancer and its relationship with estrogen and progesterone receptors].
Díez Gibert O; Machuca I; Sebastián MA; Rosel P; Navarro MA
Med Clin (Barc); 1996 Jun; 107(3):90-2. PubMed ID: 8754494
[TBL] [Abstract][Full Text] [Related]
5. Up-regulation of pS2 expression during the development of adenocarcinomas but not squamous cell carcinomas of the uterine cervix, independently of expression of c-jun or oestrogen and progesterone receptors.
Saegusa M; Hashimura M; Hara A; Okayasu I
J Pathol; 2000 Apr; 190(5):554-63. PubMed ID: 10727981
[TBL] [Abstract][Full Text] [Related]
6. [Expression of pS2-protein in breast cancer].
Kawabata K; Watanabe K; Ozaki S
Rinsho Byori; 1996 Jul; 44(7):647-52. PubMed ID: 8741495
[TBL] [Abstract][Full Text] [Related]
7. The pS2 gene, mRNA, and protein: a potential marker for human breast cancer.
Rio MC; Chambon P
Cancer Cells; 1990; 2(8-9):269-74. PubMed ID: 2223388
[TBL] [Abstract][Full Text] [Related]
8. Association of the human spasmolytic polypeptide and an estrogen-induced breast cancer protein (pS2) with human pancreatic carcinoma.
Welter C; Theisinger B; Seitz G; Tomasetto C; Rio MC; Chambon P; Blin N
Lab Invest; 1992 Feb; 66(2):187-92. PubMed ID: 1735955
[TBL] [Abstract][Full Text] [Related]
9. Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa.
Rio MC; Bellocq JP; Daniel JY; Tomasetto C; Lathe R; Chenard MP; Batzenschlager A; Chambon P
Science; 1988 Aug; 241(4866):705-8. PubMed ID: 3041593
[TBL] [Abstract][Full Text] [Related]
10. Prognostic value of pS2 protein and receptors for epidermal growth factor (EGF-R), insulin-like growth factor-1 (IGF-1-R) and somatostatin (SS-R) in patients with breast and ovarian cancer.
Foekens JA; van Putten WL; Portengen H; Rodenburg CJ; Reubi JC; Berns PM; Henzen-Logmans SC; van der Burg ME; Alexieva-Figusch J; Klijn JG
J Steroid Biochem Mol Biol; 1990 Dec; 37(6):815-21. PubMed ID: 2178364
[TBL] [Abstract][Full Text] [Related]
11. Synthetic antiestrogens modulate induction of pS2 and cathepsin-D messenger ribonucleic acid by growth factors and adenosine 3',5'-monophosphate in MCF7 cells.
Chalbos D; Philips A; Galtier F; Rochefort H
Endocrinology; 1993 Aug; 133(2):571-6. PubMed ID: 8344199
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer-associated protein pS2 expression in tumors of the biliary tract.
Seitz G; Thelsinger B; Tomasetto G; Rio MC; Chambon P; Blin N; Welter G
Am J Gastroenterol; 1991 Oct; 86(10):1491-4. PubMed ID: 1928043
[TBL] [Abstract][Full Text] [Related]
13. Quantitative analysis of follicle-stimulating hormone receptor in ovarian epithelial tumors: a novel approach to explain the field effect of ovarian cancer development in secondary mullerian systems.
Wang J; Lin L; Parkash V; Schwartz PE; Lauchlan SC; Zheng W
Int J Cancer; 2003 Jan; 103(3):328-34. PubMed ID: 12471615
[TBL] [Abstract][Full Text] [Related]
14. Prediction of relapse and survival in breast cancer patients by pS2 protein status.
Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P
Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435
[TBL] [Abstract][Full Text] [Related]
15. Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence.
Caruso JA; Karakas C; Zhang J; Yi M; Albarracin C; Sahin A; Bondy M; Liu J; Hunt KK; Keyomarsi K
Breast Cancer Res; 2014; 16(6):3417. PubMed ID: 25551582
[TBL] [Abstract][Full Text] [Related]
16. pS2 and PAI-1 in ovarian cancer: correlation to pathohistological parameters.
Speiser P; Mayerhofer K; Kucera E; Roch G; Mittelböck M; Gitsch G; Zeillinger R
Anticancer Res; 1997; 17(1B):679-83. PubMed ID: 9066601
[TBL] [Abstract][Full Text] [Related]
17. Expression of pS2 estrogen-inducible protein in primary breast cancer.
Horiguchi J; Iino Y; Takei H
Oncology; 1996; 53(1):12-5. PubMed ID: 8570124
[TBL] [Abstract][Full Text] [Related]
18. Relation of epidermal growth factor receptor and estrogen receptor-independent pS2 protein to the malignant transformation of mucinous cystic neoplasms of the pancreas.
Kirby RE; Lewandrowski KB; Southern JF; Compton CC; Warshaw AL
Arch Surg; 1995 Jan; 130(1):69-72. PubMed ID: 7802579
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of pS2 mRNA in breast cancer.
Wysocki SJ; Iacopetta BJ; Ingram DM
Eur J Cancer; 1994; 30A(12):1882-4. PubMed ID: 7880621
[TBL] [Abstract][Full Text] [Related]
20. [pS2 protein and breast cancer].
Torre EA; Fulco RA
Minerva Ginecol; 1995 Dec; 47(12):553-6. PubMed ID: 8720977
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
